ASTCT Consensus Recommendations on Testing and Treatment of Patients with Donor-specific Anti-HLA Antibodies
Piyanuch Kongtim,Pongthep Vittayawacharin,Jun Zou,Samer Srour,Brian Shaffer,Roman M Shapiro,Ankur Varma,Joseph McGuirk,Bhagirathbhai R Dholaria,Shannon R McCurdy,Amy E DeZern,Nelli Bejanyan,Asad Bashey,Sabine Furst,Luca Castagna,Jacopo Mariotti,Annalisa Ruggeri,Rebeca Bailen,Takanori Teshima,Huang Xiao-Jun,Carmen Bonfim,Fleur Aung,Kai Cao,Paul A Carpenter,Mehdi Hamadani,Medhat Askar,Marcelo Fernandez-Vina,Alin Girnita,Stefan O Ciurea
DOI: https://doi.org/10.1016/j.jtct.2024.09.005
2024-09-10
Abstract:Donor-specific anti-HLA antibodies (DSA) are an important cause of engraftment failure and may negatively impact survival outcomes of patients receiving allogeneic hematopoietic stem cell transplantation (HSCT) using an HLA-mismatched allograft. The incidence of DSA varies across studies, depending on individual factors, detection or identification methods and thresholds considered clinically relevant. Although DSA testing by multiplex bead arrays remains semiquantitative, it has been widely adopted as a standard test in most transplant centers. Additional testing to determine risk of allograft rejection may include assays with HLA antigens in natural conformation, such as flow cytometric crossmatch, and/or antibody binding assays, such as C1q testing. Patients with low level of DSA (<2,000 mean fluorescence intensity; MFI) may not require treatment, while others with very high level of DSA (>20,000 MFI) may be at very high-risk for engraftment failure despite current therapies. By contrast, in patients with moderate or high level of DSA, desensitization therapy can successfully mitigate DSA levels and improve donor cell engraftment rate, with comparable outcomes to patients without DSA. Treatment is largely empirical and multimodal, involving the removal, neutralization, and blocking of antibodies, as well as inhibition of antibody production to prevent activation of the complement cascade. Desensitization protocols are based on accumulated multicenter experience, while prospective multicenter studies remain lacking. Most patients require a full intensity protocol that includes plasma exchange, while protocols relying only on rituximab and intravenous immunoglobulin may be sufficient for patients with lower DSA levels and negative C1q and/or flow cytometric crossmatch. Monitoring DSA levels before and after HSCT could guide preemptive treatment when high levels persist after stem cell infusion. This paper aims to standardize current evidence-based practice and formulate future directions to improve upon current knowledge and advance treatment for this relatively rare, but potentially serious complication in allogeneic HSCT recipients.